Literature DB >> 1746917

Relationship of the epidermal growth factor-receptor to the growth fraction (Ki-67 antibody) and the flow cytometric S-phase as cell kinetics parameters, in human mammary carcinomas.

G Gasparini1, M Reitano, P Bevilacqua, S Meli, F Pozza, G Santini.   

Abstract

Epidermal growth factor (EGF) has been shown to have a mitogenic effect on some breast cancer cells lines in vitro. The growth of the subclass of human breast tumors which expresses the specific receptor for EGF seems to be mediated by autocrine mechanisms rather than steroid hormones. The expression of EGF-receptor, as detected by an immunocytochemical method, was compared with the Growth Fraction (GF) by the Ki-67 monoclonal antibody and the S-phase content as tumor proliferative activity indexes, and with DNA ploidy and some pathologic features in 86 stage I-II breast carcinomas. Overall 52 out of 86 (60%) of the tumors were EGF-receptor positive. There was no correlation between the cell kinetics parameters and the EGF-receptor status, suggesting that its expression may be unrelated to the proliferative activity of the tumor in these clinical stages and that the EGF-receptor GF and S-phase may be independent variables in breast cancer. In our series 57% of tumors were DNA aneuploid and only a trend was found towards EGF-receptor positivity (P = 0.08). There was no correlation between EGF-receptor expression and grading or node-status. The overall picture is that of an independent relationship between EGF-receptor with the cell kinetics parameters and ploidy, confirming the complex and heterogeneous biology of breast carcinoma. These results suggest the possibility of better recognition of subsets of patients with diverse tumor aggressiveness, combining together EGF-receptor status, cell kinetics and ploidy, with a better stratification for treatment options.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1746917

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  7 in total

1.  Peritumoral lymphatic vessel invasion compared with DNA ploidy, proliferative activity, and other pathologic features as prognostic indicators in operable breast cancer.

Authors:  G Gasparini; S Meli; G A Panizzoni; A Visonà; P Boracchi; P Bevilacqua; E Marubini; F Pozza
Journal:  Breast Cancer Res Treat       Date:  1992-03       Impact factor: 4.872

2.  Epidermal growth factor receptor in breast cancer: correlation of quantitative immunocytochemical assays to prognostic factors.

Authors:  C Charpin; B Devictor; P Bonnier; L Andrac; M N Lavaut; C Allasia; L Piana
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

3.  The prognostic significance of epidermal growth factor receptor expression in breast cancer.

Authors:  M Noguchi; Y Mizukami; K Kinoshita; M Earashi; M Thomas; I Miyazaki
Journal:  Surg Today       Date:  1994       Impact factor: 2.549

4.  Progesterone receptor determined by immunocytochemical and biochemical methods in human breast cancer.

Authors:  G Gasparini; F Pozza; R Dittadi; S Meli; S Cazzavillan; P Bevilacqua
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

5.  Clinical value of enzyme immunoassay of epidermal growth factor receptor in human breast cancer.

Authors:  H Iwase; S Kobayashi; Y Itoh; T Kuzushima; H Yamashita; H Iwata; A Naito; T Yamashita; K Itoh; A Masaoka
Journal:  Breast Cancer Res Treat       Date:  1993-12       Impact factor: 4.872

6.  Feasibility and clinical applications of multiple breath wash-out (MBW) testing using sulphur hexafluoride in adults with bronchial asthma.

Authors:  Frederik Trinkmann; Steffi A Lenz; Julia Schäfer; Joshua Gawlitza; Michele Schroeter; Tobias Gradinger; Ibrahim Akin; Martin Borggrefe; Thomas Ganslandt; Joachim Saur
Journal:  Sci Rep       Date:  2020-01-30       Impact factor: 4.379

7.  Value of epidermal growth factor receptor status compared with growth fraction and other factors for prognosis in early breast cancer.

Authors:  G Gasparini; P Bevilacqua; F Pozza; S Meli; P Boracchi; E Marubini; J R Sainsbury
Journal:  Br J Cancer       Date:  1992-11       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.